Life Sciences
The Ministry of Health has submitted a far-reaching amendment that would revise the Healthcare Digitalisation Act, the Medicinal Products Act, and the Health Services Act. The amendment represents the first stage of implementing the EU Regulation on the European Health Data Space (EHDS). In addition
Compensation claims for personal injury in cases of progressive diseases
From what point may a patient suffering from a progressive disease bring a claim for compensation for personal injury caused by vaccination with a defective vaccine? Is the expiry of the ten-year limitation period, regardless of whether the claimant’s medical condition has stabilised, compatible wit
Advertising of Medical Devices: Rules in Force Since 2021—Yet Still Not Widely Known on the Market
In March 2026, the State Institute for Drug Control (SÚKL) issued a new notice that deserves close attention. The Czech regulator reiterates a key rule: advertising aimed at the general public must not promote medical devices that, under the manufacturer’s instructions, are intended solely for use b
Generic or Biosimilar Entry: Reimbursement cuts now tied to verified market availability
Reimbursement for original medicinal products gradually decreases over time – it “erodes”. A key factor in this process is the entry of the first generic (Gx) or biosimilar (Bx) into the reimbursement system. This usually leads to a broad reduction in reimbursement across the entire reference group
Central purchasing of medicines in Czechia – how will it work and can it really bring savings?
A notable novelty has taken effect as of 1 January 2026. Under an amendment to the Czech Public Health Insurance Act, public health insurance companies can now centrally procure the purchase of selected medicines that are intended for hospitals with the status of highly specialised care centres. The
New rules for vaccine reimbursement: When higher consumption leads to savings for the whole society
On 1 January 2026, an amendment to the Public Health Insurance Act entered into force, introducing a completely new reimbursement rules for vaccines and monoclonal antibodies intended for prophylaxis (“vaccines”). Under the new framework, decisions regarding reimbursement for vaccines will be made i
New price regulations of the Ministry of Health for 2026: What is changing and what to watch out for
As of 1 January 2026, new price regulations issued by the Ministry of Health of the Czech Republic will come into force, governing the prices of medicinal products, medical devices, and healthcare services. In addition to partial content-related changes, they also introduce a major systemic novelty
GLP-1 in the Food Industry: Can We Expect “GLP-1 Friendly Foods” Also in the EU?
The rising popularity of GLP-1-based medications, such as semaglutide and liraglutide, is not only reshaping how people approach weight loss, but is also beginning to influence the food industry. While pharmaceutical companies are seeing a surge in demand for obesity treatments, food producers are f
Telemedicine and cross-border healthcare: CJEU clarifies the rules
In September 2025, the Court of Justice of the European Union (CJEU) issued a landmark judgment on the provision of healthcare through telemedicine within the EU. The decision clarifies the rules governing cross-border healthcare, particularly in relation to telemedicine, and sets out which laws app
SZPI in action: Most common violations and how to avoid them
The Czech Agriculture and Food Inspection Authority (Státní zemědělská a potravinářská inspekce or SZPI) conducts thousands of inspections of food businesses every year. A look back at the previous year reveals notable trends in inspectors’ decision-making – particularly a sharp increase in the tota
Authors



.jpg.webp?hash=ddde4fb3f59badd04c202fa9465083fbd2e841ea)

















